Clinical Trial Update: An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE) [EARLY_Phase 1]

View source ↗

Summary

An open-label, multi-dose Phase 1 study evaluated the safety and potential long-lasting effects of a CRISPR gene-editing therapy in Duchenne muscular dystrophy;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• CRISPR gene-editing therapy

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: Duchenne Muscular Dystrophin (DMD) | EARLY_Phase 1 | Status: COMPLETED